Part of the challenge has been the distribution of cost structure under the Oncology Care Model (OCM), particularly with respect to pharmaceuticals, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
Part of the challenge has been the distribution of cost structure under the Oncology Care Model (OCM), particularly with respect to pharmaceuticals, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
Transcript
For practices participating in the OCM that have not improved in performance period 3, what are their biggest challenges in trying to do so?
It’s a complicated subject, and there’s different kind of buckets of where is performance lacking. I’d say that overall, there’s been really good progress it seems, in aggregate, around preventing hospitalizations and doing things like that—skilled nursing facility utilization, diminishing that. I think part of the challenge has been the distribution of the cost structure, particularly with respect to pharmaceuticals. I think for many participants, they feel like that’s largely out of their control. They feel that their care is roughly in line with the evidence-based guidelines, particularly NCCN [National Comprehensive Cancer Network] guidelines. So, the price of pharmaceuticals is difficult for them to manage, and they feel like it’s outside the span of their control. So, I think this has been one of the occurring issues.
I think other issues in terms of performance, I think one thing we see is for many practices, it’s been hard for them to actually interpret what’s driving their performance, particularly what cancers are problematic with respect to methodology or where are they going over, understanding what’s driving that, how effective are different interventions they have going on. There’s a constellation of different issues. I think parallel to that, there are different issues related to the model’s methodology itself. Are prices being projected accurately or in line with what’s actually happening? Things like that. There’s a lot of complex financial modeling that’s involved in OCM, and a lot of what’s being done is predicting prices, and that’s a complicated thing to do in a domain such as oncology.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More